Special departments of the First People's Hospital of Huai 'an City

ICU (Department of Critical Care Medicine) of the First Hospital of the City was established in February 1991, which is the earliest clinical professional ward with comprehensive ability and the largest scale in our city to centrally rescue acute and critical patients. After more than 2 years of construction and development, the scale and requirements of modern hospital ICU have begun to take shape. ICU has 12 beds, including 1 chief physician, 1 deputy chief physician, 2 attending physicians, 4 residents, 1 doctoral student, 5 master students, 26 nurses and 8 health workers. With the unique service concept of ICU and strengthening medical mode, this department has made outstanding contributions to the treatment of critical patients in the whole hospital and achieved good social benefits. The number of critically ill patients is about 2 per year, and the success rate of rescue is over 89.%.

This department mainly treats critical patients in internal and external surgery, such as various kinds of shock, respiratory cardiac arrest, cardiopulmonary cerebral resuscitation, first aid for severe trauma, severe infection, severe poisoning, severe arrhythmia, severe complications after major surgery, acute respiratory distress syndrome, severe asthma, DIC, multiple organ dysfunction syndrome, etc. In particular, he is good at monitoring and treatment of vital indicators of critically ill patients, clinical application technology of ventilators, mild hypothermia treatment of brain resuscitation, continuous blood purification treatment of critically ill patients at bedside, systemic support of critically ill patients and nutritional support inside and outside the intestine. Hematology Department of the First Hospital of City is the first clinical key specialty in Huai 'an and the key discipline of Nanjing Medical University during the Eleventh Five-Year Plan period. There are 29 medical and nursing staff, including 1 excellent medical talent in Jiangsu Province, 2 trained objects in the provincial "333 Project", 1 trained object in the first level of the "1 Project" in Huai 'an, 2 doctoral students, 4 master students and 3 chief physicians. There are 48 open beds, including 2 laminar flow wards. There are more than 1, outpatient visits and more than 1, discharged patients. It has an advanced hematology laboratory, which is the diagnosis and treatment center of hematology in Huai 'an and surrounding counties and cities, and the base of hematology, science, research and teaching in Huai 'an.

He has rich experience in the diagnosis and treatment of various common and difficult critical blood diseases. Autologous bone marrow transplantation was first carried out in northern Jiangsu in 199 to treat hematological malignancies. In 1996, homoharringtonine was first used to treat chronic granulocytes and MEA was used to treat acute non-lymphocytic leukemia in China. Tripterygium wilfordii polyglycoside has achieved good results in treating severe aplastic anemia and has been adopted by many hospitals in China. At present, advanced technologies such as high-dose chemotherapy, allogeneic and autologous peripheral blood stem cell transplantation for leukemia and malignant lymphoma, plasma exchange, donor lymphocyte infusion, bone marrow stromal cells for acute myocardial infarction and cerebral infarction, and CIK immune cells for malignant tumors are being carried out, and the curative effect has reached the advanced level in China. The laboratory covers an area of 4 square meters, and has more than 2 sets of equipment (including CO2 incubator, PCR amplifier, Benchman Coulter flow cytometer, fluorescence microscope, freezing centrifuge, -8℃ low-temperature refrigerator, gel imaging system, bone marrow blood cell imaging system, etc.). In addition to routine cell morphology, immunological examination, and blood coagulation disease examination, it also has mastered chromosome karyotype analysis of malignant tumors and blood diseases and FISH analysis of cells. The Clinical Reproductive Medicine Center of the First People's Hospital of Huai 'an is a clinical department of our hospital, offering outpatient service for infertility. It is the Huai 'an branch of jiangsu province hospital Clinical Reproductive Medicine Center, which is mainly devoted to the standardized clinical diagnosis and treatment of male and female infertility and related basic research, actively developing various new technologies for diagnosis and treatment, and serving infertile couples in Huai 'an and surrounding areas, so that they can have a healthy and lovely baby as soon as possible.

In the treatment of male and female infertility, we cooperated with jiangsu province hospital to carry out standardized outpatient screening, such as ovulation monitoring, endocrine examination, semen examination, lipiodol angiography, etc. In the field of reproductive endocrine, we are familiar with infertility caused by ovulation disorder, such as premature ovarian failure, polycystic ovary syndrome, sexual dysplasia, dysfunctional uterine bleeding, amenorrhea, endometriosis and hyperprolactinemia. At the same time, it is the best choice for patients to cooperate with jiangsu province hospital Clinical Reproductive Medicine Center to carry out two-way referral, enjoy medical resources and carry out various examinations and treatments of artificial insemination and IVF. Cardiovascular Department of the First Hospital of City is a key clinical specialty in Huai 'an. There are 15 physicians at all levels, including 3 chief physicians, 3 deputy chief physicians, 4 attending physicians and 4 graduate students. The current director is Ma Shuren, the chief physician. There are many physicians in the Department of Cardiology who are members of the Cardiovascular Specialist Society of Jiangsu Medical Association, members of the Intervention Group of Coronary Heart Disease in Jiangsu Province, and the chairman, vice-chairman and secretary of the Cardiovascular Specialist Society of Huai 'an Medical Association.

Cardiovascular specialist clinics treat more than 2, patients every year, including pacemaker clinics and paroxysmal supraventricular tachycardia clinics. There are 54 beds in the ward, and more than 2, patients are treated each year. There are also professional groups of coronary heart disease and pacing and electrophysiology in the Department of Cardiology. The ward has advanced telemetering ECG monitoring system covering the whole ward, cardiac DSA catheter room, dual invasive multifunctional monitors, multi-conductive physiological recorders, as well as dynamic electrocardiogram, ambulatory blood pressure, ventricular late potential, exercise treadmill, cardiac color Doppler and other equipment, which can meet the needs of diagnosis and treatment of various heart diseases with advanced equipment such as 64-slice spiral CT, myocardial radionuclide imaging (ECT) and nuclear magnetic resonance imaging.

Cardiology Department is the only unit in Huai 'an that has been approved by Jiangsu Provincial Health Department to carry out interventional diagnosis and treatment of cardiovascular diseases. Born in 196, director, chief physician, dean and secretary of the Party Committee of the First Hospital of the City. Chairman of Huai 'an Neurosurgery Academic Committee, member of Jiangsu Neurosurgery Academic Committee, head of the Spinal Cord Department, and "333 Project" talent in Jiangsu Province. Associate professor and master tutor of South Medical University. In 1998, he was named "Top Ten Outstanding Youth" (model worker) in Huaiyin City, awarded outstanding scientific and technological workers in Huai 'an City in 21, and won the "May 1st" Labor Medal in Jiangsu Province in 22.

I graduated from Nanjing Medical College in p>1982 and have been engaged in neurosurgery since I was admitted to the hospital in the same year. He studied hard and went to Beijing Tiantan Hospital, Xijing Hospital affiliated to the Fourth Military Medical University, and Children's Hospital affiliated to the University of Toronto for further study. Under the guidance of famous neurosurgery experts such as Academician Wang Zhongcheng and Professor Dr.Drake, he carried out difficult operations such as craniocerebral injury, cerebrovascular disease, spinal intramedullary tumor resection and pediatric neurosurgery. Neuromicrosurgery and microsurgery of intramedullary spinal cord tumors were carried out earlier in the province. The operation was thorough and clean, and all patients recovered well after operation. Proficient in microsurgical resection of skull base tumors, jugular tumors and auditory neuralgia, with high total resection rate, few surgical complications and no surgical death. In 1994, he took the lead in carrying out direct surgery for intracranial aneurysms in the city and won the Municipal Science and Technology Progress Award; Superselective interventional chemotherapy carried out in 1996 brought good news to patients with advanced or recurrent brain tumors; Autologous bone marrow stem cell transplantation in 24 explored a new way to treat severe brain dysfunction. He attached great importance to the summarization and popularization of experience, published more than ten professional academic papers in core journals inside and outside the province, and won the second prize of the municipal scientific and technological progress twice and the third prize five times. Born in 1955, chief physician, vice president, professor and master tutor of hematology department of the hospital. In 1996, he was awarded as an outstanding intellectual in Jiangsu Province, a young and middle-aged expert with outstanding contributions in Jiangsu Province in 1999, a hundred outstanding medical talents in Jiangsu Province in 2, a special government allowance approved by the State Council since 25, and a title of model worker by the Jiangsu Provincial Government in 26. In 27, he was awarded the National May 1st Labor Medal, the chairman of Huai 'an City, the vice chairman of Huai 'an CPPCC, and the first member of Chinese People's Political Consultative Conference in Huai 'an City.

Li Yufeng has a solid medical theory foundation, rigorous business technology, enthusiasm for patients and noble medical ethics. After studying in Italy in 1994, he refused to be retained by his tutor, and returned to China to come to the hospital. Combining theory with practice, he has accumulated rich experience in clinical practice, and is good at finding problems and making continuous progress. It is the first time to use MEA regimen to treat acute leukemia and tripterygium wilfordii polyglycoside to treat severe aplastic anemia in China, which has attracted great attention from peers. In 1999, with the support of the Ministry of Education, I went to study in St. Louis Hospital in Paris, France, during which I completed two scientific researches. After returning to China, more than ten new technologies and projects representing the high level in the field of hematology, such as CIK cell therapy for malignant tumors, MICM diagnosis of acute leukemia, allogeneic hematopoietic stem cell transplantation for malignant hematological diseases and haploidentical hematopoietic stem cell transplantation, have been carried out successively, and more than 4 research papers have been published in academic journals at all levels, including one in British Journal of Hematology and The Lancet, and one in Chinese series magazines such as Chinese Journal of Hematology. Won the third prize of Jiangsu Science and Technology Progress Award, more than 1 prizes of Huai 'an Science and Technology Progress Award, including 2 first prizes. In 26, the research achievement "Study on the Long-term Efficacy and Mechanism of Homoharringtonine in the Treatment of Chronic Myeloid Leukemia" won the first prize of the Municipal Science and Technology Progress Award, which was highly praised by well-known experts in China, and it was considered as an innovative research on the mechanism of action in the treatment of Chronic Myeloid Leukemia, reaching the leading level in China. The hematology department led by him has reached the domestic advanced level in the diagnosis and treatment of leukemia, aplastic anemia, thrombocytopenic purpura and other diseases. In 22, hematology department was identified as a provincial key specialty, and in 26, it became a key discipline of Nanjing Medical University. In 26, it was confirmed by the provincial health department as the first department with the qualification of unrelated hematopoietic stem cell transplantation. Male, born in 1967, from Shuyang, Jiangsu Province, doctor of medicine, chief physician, associate professor of Nanjing Medical University, and tutor of postgraduate students. He graduated from Huaiyin Middle School in Jiangsu Province in 1984, studied in the Department of Clinical Medicine of Nantong Medical College from 1984 to 1989, and graduated with a bachelor's degree. In the same year, he entered the pediatric department of the First People's Hospital of Huaiyin (An) City, and served as a resident, attending physician, deputy chief physician and chief physician. During the period, he obtained a master's degree in pediatrics from Nanjing Medical University in 1998, majoring in neonatal diseases, and graduated in 2 with a master's degree in pediatrics. In 24, he entered Southern Medical University to study for a doctorate in pediatrics, and his major direction was the basic and clinical research of critical illness in children. Graduated in 27, received a doctorate in pediatrics, and won the title of outstanding graduate student in Nanyue, Guangdong Province in 27.

clinical specialty: neonatal diseases and critical diseases of children. After many years of postgraduate study, I have a solid professional theoretical foundation and 2 years of clinical work experience, and I am good at rescuing critically ill children and newborns, postoperative management of common neonatal surgical diseases, and transportation of critically ill children. He has some experience in neonatal resuscitation, pulmonary surfactant replacement therapy for hyaline membrane disease, neonatal parenteral nutrition, treatment of very low birth weight infants, exchange transfusion therapy for neonatal hyperbilirubinemia, and nitric oxide inhalation therapy for neonatal pulmonary hypertension.